- Conditions
- Hyperactivity in Children With Down Syndrome, Impulsivity in Children With Down Syndrome
- Interventions
- Guanfacine Hydrochloride Immediate Release, Placebo
- Drug
- Lead sponsor
- Rachel G. Greenberg, MD, MB, MHS
- Other
- Eligibility
- 6 Years to 12 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 14
- States / cities
- Phoenix, Arizona • Atlanta, Georgia • Chicago, Illinois + 11 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–10
of 10
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Healthy Volunteers
- Interventions
- immediate release guanfacine hydrochloride, moxifloxacin, Placebo
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 83 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008
- U.S. locations
- 1
- States / cities
- Tacoma, Washington
- Conditions
- Depression
- Interventions
- Guanfacine, Sertraline
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 162 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 2
- States / cities
- Palo Alto, California • Chicago, Illinois
- Conditions
- Delirium
- Interventions
- Guanfacine, Placebo
- Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Stress Disorder
- Interventions
- Guanfacine Extended Release, Mindfulness Skills Therapy, Placebo
- Drug · Behavioral
- Lead sponsor
- UConn Health
- Other
- Eligibility
- 10 Years to 20 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Farmington, Connecticut
- Conditions
- Smoking
- Interventions
- Guanfacine
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Prader-Willi Syndrome, Aggression, Self-Injurious Behavior, Pathologic Processes, Behavioral Symptoms, Intellectual Disability, Neurobehavioral Manifestations, Neurologic Manifestations, Nervous System Diseases, Abnormalities, Multiple, Congenital Abnormalities, Chromosome Disorders, Genetic Diseases, Inborn, Obesity, Overnutrition, Nutrition Disorders, Antihypertensive Agents, Neurotransmitter Agents, Molecular Mechanisms of Pharmacological Action, Physiological Effects of Drugs, Skin-Picking
- Interventions
- Guanfacine Extended Release, Placebo
- Drug · Other
- Lead sponsor
- Maimonides Medical Center
- Other
- Eligibility
- 6 Years to 35 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Brooklyn, New York
- Conditions
- Attention-Deficit/Hyperactivity Disorder (ADHD)
- Interventions
- Guanfacine (GUA), Methylphenidate (MPH)
- Drug
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- 3 Years to 5 Years
- Enrollment
- 370 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 5
- States / cities
- Palo Alto, California • Boston, Massachusetts • Kansas City, Missouri + 2 more
- Conditions
- Prader-Willi Syndrome
- Interventions
- Placebo, Guanfacine extended release (GXR)
- Other · Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 6 Years to 35 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Major Depressive Disorder
- Interventions
- Guanfacine Tablets
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years to 69 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Palo Alto, California